Evidence map›Paper›PMID 40688200›Full record

ArticleInternational journal of cardiology. Heart & vasculature2025

Effects of pulmonary endarterectomy and balloon pulmonary angioplasty in older adults with chronic thromboembolic pulmonary hypertension: A sub-analysis of the CTEPH AC registry.

Jun Yamashita, Hitoshi Ogino, Kohei Masaki, Yu Taniguchi, Shiro Adachi, Takumi Inami, Kazuya Hosokawa, Ichizo Tsujino, Nobuhiro Yaoita, Masaru Hatano and 15 more

Abstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Jun YamashitaDepartment of Cardiology, Tokyo Medical University, Tokyo, Japan.
Hitoshi OginoDepartment of Cardiovascular Surgery, Tokyo Medical University, Tokyo, Japan.
Kohei MasakiDepartment of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Yu TaniguchiDepartment of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Shiro AdachiDepartment of Cardiology, Nagoya University Hospital, Nagoya, Japan.
Takumi InamiDepartment of Cardiovascular Medicine, Kyorin University School of Medicine, Mitaka, Japan.
Kazuya HosokawaDepartment of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Ichizo TsujinoDepartment of Respirology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Nobuhiro YaoitaDepartment of Cardiovascular Medicine, Tohoku University Hospital, Sendai, Japan.
Masaru HatanoDepartment of Cardiovascular Medicine, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan.
Nobutaka IkedaDivision of Cardiovascular Medicine, Toho University Medical Center Ohashi Hospital, Tokyo, Japan.
Nobuhiro TanabePulmonary Hypertension Center, Chibaken Saiseikai Narashino Hospital, Narashino, Japan.
Hiroto ShimokawaharaDepartment of Cardiology, NHO Okayama Medical Center, Okayama, Japan.
Kayoko KubotaDepartment of Cardiovascular Medicine and Hypertension, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Ayako ShigetaDepartment of Respirology, Chiba University Graduate School of Medicine, Chiba, Japan.
Koshin HorimotoDepartment of Cardiovascular Medicine, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Yoshito OgiharaDepartment of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu, Japan.
Yoshihiro DohiDepartment of Cardiovascular Medicine, Kure Kyosai Hospital, Kure, Japan.
Takahiro HiraideDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Takashi KawakamiDivision of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Hidekazu IkemiyagiDepartment of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan.
Yuichi TamuraPulmonary Hypertension Center, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Yoshihiro FukumotoDivision of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.
Kohtaro AbeDepartment of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
CTEPH AC Registry Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Invasive treatments for chronic thromboembolic pulmonary hypertension (CTEPH) include pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA). Both PEA and BPA demonstrate significant benefits for symptom relief, hemodynamic improvement, and overall patient outcomes. However, evidence of their efficacy in older adults remains limited. This study aimed to evaluate treatment efficacy-including exercise tolerance, hemodynamics, functional status-and clinical outcomes in CTEPH patients aged ≥70 years who underwent PEA or BPA. Methods: Among 1,527 patients in the CTEPH AntiCoagulants Registry, we selected those aged 70 years or older, including 25 who underwent PEA during follow-up and 210 who received BPA. We evaluated the World Health Organization functional class (WHO FC), a measure of subjective symptoms, along with exercise capacity, hemodynamic parameters, and clinical outcomes. Results: At baseline, BPA patients were older (P = 0.003) and tended to have lower body weight (P = 0.069) than those undergoing PEA. At a median follow-up of ∼2 years, BPA significantly improved six-minute walk distance and cardiac index, and reduced mean pulmonary artery pressure and pulmonary vascular resistance, with effects comparable to PEA after adjusting for age, sex, and body mass index (all adjusted P > 0.10). However, improvement in WHO FC was more frequent with BPA and became significant after covariate adjustment (adjusted P = 0.035). Adverse event rates were infrequent and similar between the two groups (all P > 0.10). Conclusions: In adults aged ≥ 70 years with CTEPH, BPA improved hemodynamics, exercise capacity, and outcomes comparable to PEA, but with greater WHO FC improvement. Further randomized trials in older adults are warranted. Clinical trial registration number: UMIN Clinical Trials Registry (identifier UMIN 000033784).

Indexed as

Balloon pulmonary angioplastyChronic thromboembolic pulmonary hypertensionOlder adultsPulmonary endarterectomy

Identifiers

PMID40688200
PMCPMC12274849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.